BDA-366
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 407377

CAS#: 1821496-27-8

Description: BDA-366 is a BCL2-BH4 antagonist. BDA-366 suppresses human myeloma growth. BDA-366 induces robust apoptosis in MM cell lines and primary MM cells by inducing BCL2 conformational change. Delivery of BDA-366 substantially suppressed the growth of human MM xenografts in NOD-scid/IL2Rγnull mice, without significant cytotoxic effects on normal hematopoietic cells or body weight. Thus, BDA-366 functions as a novel BH4-based BCL2 inhibitor and offers an entirely new tool for MM therapy.


Price and Availability

Size
Price

10mg
USD 250
100mg
USD 1250
1g
USD 3850
Size
Price

20mg
USD 450
200mg
USD 1950
2g
USD 5950
Size
Price

50mg
USD 750
500mg
USD 2750
5g
USD 9950

BDA-366, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 407377
Name: BDA-366
CAS#: 1821496-27-8
Chemical Formula: C24H29N3O4
Exact Mass: 423.2158
Molecular Weight: 423.513
Elemental Analysis: C, 68.06; H, 6.90; N, 9.92; O, 15.11


Synonym: BDA-366; BDA 366; BDA366.

IUPAC/Chemical Name: 1-(((S)-3-(diethylamino)-2-hydroxypropyl)amino)-4-((((S)-oxiran-2-yl)methyl)amino)anthracene-9,10-dione

InChi Key: JYOOEVFJWLBLKF-HOTGVXAUSA-N

InChi Code: InChI=1S/C24H29N3O4/c1-3-27(4-2)13-15(28)11-25-19-9-10-20(26-12-16-14-31-16)22-21(19)23(29)17-7-5-6-8-18(17)24(22)30/h5-10,15-16,25-26,28H,3-4,11-14H2,1-2H3/t15-,16-/m0/s1

SMILES Code: CCN(CC)C[C@@H](O)CNC1=CC=C(NC[C@@H]2OC2)C3=C1C(C4=C(C3=O)C=CC=C4)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Deng J, Park D, Wang M, Nooka A, Deng Q, Matulis S, Kaufman J, Lonial S, Boise LH, Galipeau J, Deng X. BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth. Oncotarget. 2016 May 10;7(19):27753-63. doi: 10.18632/oncotarget.8513. PubMed PMID: 27049723; PubMed Central PMCID: PMC5053685.

2: Han B, Park D, Li R, Xie M, Owonikoko TK, Zhang G, Sica GL, Ding C, Zhou J, Magis AT, Chen ZG, Shin DM, Ramalingam SS, Khuri FR, Curran WJ, Deng X. Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy. Cancer Cell. 2015 Jun 8;27(6):852-63. doi: 10.1016/j.ccell.2015.04.010. PubMed PMID: 26004684; PubMed Central PMCID: PMC4470473.

3: Vervloessem T, La Rovere R, Bultynck G. Antagonizing Bcl-2's BH4 domain in cancer. Aging (Albany NY). 2015 Oct;7(10):748-9. PubMed PMID: 26525307; PubMed Central PMCID: PMC4637201.

4: Liu Z, Wild C, Ding Y, Ye N, Chen H, Wold EA, Zhou J. BH4 domain of Bcl-2 as a novel target for cancer therapy. Drug Discov Today. 2016 Jun;21(6):989-96. doi: 10.1016/j.drudis.2015.11.008. Review. PubMed PMID: 26631752; PubMed Central PMCID: PMC4882289.

5: Selective Inhibition of BCL2 Shows Antitumor Effects in Lung Cancer. Cancer Discov. 2015 Jul;5(7):OF21. doi: 10.1158/2159-8290.CD-RW2015-102. PubMed PMID: 26045015.